Further, he emphasized the significance of not waiting when it comes the leveraging the newer therapies in patients—particularly the immunotherapies—and decisions should be made earlier on in the patient’s treatment. “We don't want to wait until they get to that fourth line before we start...
T cell-engaging immunotherapies exert unprecedented single-agent activity in multiple myeloma (MM), thereby putting a yet unexplored selective pressure on the clonal architecture. In this study, we report on homozygous BCMA (TNFRSF17) ge... MS Truger,J Duell,X Zhou,... - 《Blood Advances》...
Brain metastasis and cancer immunotherapies.(A)In addition to metastasized tumor cells, the tumor microenvironment (TME) of brain metastasis consists of unique cell type(s), including astrocytes/activated astrocytes, microglia cells, myeloid-derived suppressor cells (MDSCs), and neurons. The neurologica...
Furthermore, antigen-specific immunotherapies hold promise to expand the armamentarium for treatment of AML. In this review, we highlight some of the promising novel approaches and agents that are currently in clinical trials and have published or presented data. This article is not meant to be ...
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197–218 (2019). CAS PubMed Google Scholar Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793...
This review will provide updates of the emerging therapeutic approaches for the treatment of AML, including combinations with mutation driven targeted treatments, novel immunotherapies in the myeloid disease. Targeted therapies: alone or combination BCL-2 inhibitor: venetoclax BCL-2 is a member of the...
display distinct yet overlapping functions (Fig.1). Given the development of multi-omics technologies, myeloid cells are now known to have high heterogeneity and complexity, which both create challenges and have implications for the development of myeloid cell-targeting immunotherapies [11,14,15,16,...
multiple myeloma (r/r MM), with high response rate, low recurrence rate and manageable CRS [43]. Importantly, BCMA-CAR-T immunotherapies Ciltacabtagene-autoleucel and Idecabtagene-vicleucel are now available for the treatment of patients with relapsed and refractory multiple myeloma [44]. ...
Current cancer immunotherapies are primarily predicated on αβ T cells, with a stringent dependence on MHC-mediated presentation of tumour-enriched peptides or unique neoantigens that can limit their efficacy and applicability in various contexts. After two decades of preclinical research and preliminary...
multiple myeloma (r/r MM), with high response rate, low recurrence rate and manageable CRS [43]. Importantly, BCMA-CAR-T immunotherapies Ciltacabtagene-autoleucel and Idecabtagene-vicleucel are now available for the treatment of patients with relapsed and refractory multiple myeloma [44]. ...